Alkermes Increases Offer to Buy Avadel in Bid to Outdo Lundbeck Proposal
ByAinvest
Thursday, Nov 20, 2025 10:26 am ET1min read
ALKS--
AVDL--
Alkermes ALKS has increased its offer to buy Avadel Pharmaceuticals AVDL to $22.50 per share, valuing the deal at $2.37 billion. This follows Lundbeck's unsolicited offer to acquire Avadel for up to $23.00 per share. Alkermes' revised offer includes a $21.00 cash payment and a non-transferable CVR worth up to $1.50, payable upon FDA approval of Lumryz by December 2028. The transaction is expected to close in Q1 2026, subject to customary closing conditions.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet